Human in vivo De Novo and Recall Antibody Responses after Rituximab Treatment for Type 1 Diabetes

被引：0
|
作者：
Pescovitz, Mark [1 ]
McGee, Paula [2 ]
Krause-Steinrauf, Heidi [2 ]
Canniff, Jennifer [3 ]
Weinberg, Adriana [3 ]
Skyler, Jay [4 ]
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
[2] George Washington Univ, Rockville, MD USA
[3] Univ Colorado, Denver, CO 80202 USA
[4] Univ Miami, Miami, FL USA
来源：
CLINICAL IMMUNOLOGY | 2010年 / 135卷
关键词：
D O I：
10.1016/j.clim.2010.03.099
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] In Vivo Immune Responses in Type 1 Diabetes Following Treatment with Rituximab
    Pescovitz, Mark D.
    Torgerson, Troy R.
    Ochs, Hans D.
    Ocheltree, Elizabeth
    McGee, Paula
    Krause-Steinrauf, Heidi
    [J]. DIABETES, 2009, 58 : A51 - A51
  • [2] Effect of rituximab on human in vivo antibody immune responses
    Pescovitz, Mark D.
    Torgerson, Troy R.
    Ochs, Hans D.
    Ocheltree, Elizabeth
    McGee, Paula
    Krause-Steinrauf, Heidi
    Lachin, John M.
    Canniff, Jennifer
    Greenbaum, Carla
    Herold, Kevan C.
    Skyler, Jay S.
    Weinberg, Adriana
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (06) : 1295 - U655
  • [3] Ibrutinib Suppresses De Novo Alloantibodies and Recall Antibody Responses in a Mouse Model of Allosensitization: A Preliminary Report
    Wu, G. D.
    Kim, I.
    Chai, N.
    Klein, A. S.
    Jordan, S.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S93 - S93
  • [4] De novo mutation of PHEX in a type 1 diabetes patient
    Fang, Chen
    Li, Hui
    Li, Xiaozhen
    Xiao, Wenjin
    Huang, Yun
    Cai, Wu
    Yang, Yi
    Hu, Ji
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2016, 29 (05): : 621 - 626
  • [5] Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes
    Hale, Geoff
    Rebello, Peppy
    Al Bakir, Ibrahim
    Bolam, Emma
    Wiczling, Pawel
    Jusko, William J.
    Vandemeulebroucke, Evy
    Keymeulen, Bart
    Mathieu, Chantal
    Ziegler, Annette-G
    Chatenoud, Lucienne
    Waldmann, Herman
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (11): : 1238 - 1248
  • [6] Evolving Antibody Therapies for the Treatment of Type 1 Diabetes
    Ke, Qi
    Kroger, Charles J.
    Clark, Matthew
    Tisch, Roland M.
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [7] Exenatide and etanercept in De Novo islet transplantation for type 1 diabetes.
    Salehi, Payam
    Gangemi, Antonio
    Hatipoglu, Betul
    Martellotto, Joan
    Barbaro, Barbara
    Kuechle, Joseph
    Qi, Meirigeng
    Wang, Yong
    Pallan, Pablo
    Owens, Charles
    Bui, James
    West, Derek
    Kaplan, Bruce
    Benedetti, Enrico
    Oberholzer, Jose
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 236 - 236
  • [8] De novo Anti-HLA Antibody Responses after Renal Transplantation: Detection and Clinical Impact
    Seveso, Michela
    Bosio, Erika
    Ancona, Ermanno
    Cozzi, Emanuele
    [J]. HUMORAL IMMUNITY IN KIDNEY TRANSPLANTATION: WHAT CLINICIANS NEED TO KNOW, 2009, 162 : 87 - 98
  • [9] High incidence of de novo diabetes mellitus type 1 during or after treatment with pegylated interferon in patients with chronic hepatitis C virus infection
    Schreuder, T. C. M. A.
    Gelderblom, H. G.
    Weegink, C. J.
    Reesink, H. W.
    Hoekstra, J. B. L.
    Jansen, P. L. M.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S225 - S225
  • [10] High incidence of de novo diabetes mellitus type 1 during or after treatment with pegylated interferon in patients with chronic hepatitis C virus infection
    Hoekstra, J.
    Schreuder, T.
    Gelderblom, H.
    Weegink, C.
    Reesink, H.
    DeVries, J.
    Jansen, P.
    [J]. DIABETOLOGIA, 2006, 49 : 501 - 502
12345